Podcasts about clinical endocrinologists aace

Osteoporosis significantly impacts morbidity and mortality in the U.S., with approximately 12.3 million adults (USPSTF) in the United States aged 50 and over expected to be living with the disease. Osteoporotic fractures result in severe consequences such as functional impairment, chronic pain, reduced quality of life, and loss of independence. Furthermore, the clinical and economic burden of osteoporosis is substantial, with annual costs projected to be $25.3 billion by 2025 (AJMC).The U.S. Preventative Task Force (USPSTF) recommends screening and treatment of osteoporosis in adults. Accordingly, CommonSpirit Health, Physician Enterprise has adopted the evidence based guidelines of professional societies, including American College of Physicians (ACP), American Association of Clinical Endocrinologists (AACE), and Endocrine Society, on screening and treatment to prevent osteoporotic fractures. Speakers:Kavita Chawla, MD, MHA, FACP, Primary Care Physician, Kirkland Medical Center, Virginia Mason Franciscan HealthBryan C Jiang, MD, Internal Medicine Endocrinology, Diabetes and Metabolism, Baylor College of Medicine Houston, TexasPanelist:Anne Wright, DMSc, MPAS, PA-C, DFAAPA, System Director Advanced Practice Ambulatory Care, CommonSpirit Health

In this episode, host Dr. Jacob Fleming interviews Dr. Douglas Beall about current osteoporosis diagnosis criteria, his treatment algorithm, and recent data showing efficacy of osteoanabolic agents and vertebroplasty. --- CHECK OUT OUR SPONSOR DI4MDs https://www.di4mds.com --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs: https://earnc.me/oQMiwe --- SHOW NOTES In this episode, host Dr. Jacob Fleming interviews Dr. Douglas Beall about current osteoporosis diagnosis criteria, his treatment algorithm, and recent data showing efficacy of osteoanabolic agents and vertebroplasty. This is the second installment of our 4-part BackTable VI series on osteoporosis treatment. As we continue our conversation from Ep. 208, Dr. Beall outlines his typical follow up protocol for his patients. This includes DEXA scans in the first and second years, prescriptions for antiresorptive and/or osteoanabolic agents, and possible Romosozumab injections. Dr. Beall emphasizes that thoroughness is key to treating the disease process, and each encounter is a reimbursable event that can benefit both the patient and the practice. Next, we shift to talking about the American Association of Clinical Endocrinologists (AACE) diagnostic criteria for osteoporosis. Dr. Beall highlights the fact that there are 4 categories that encompass information about DEXA (T-scores), FRAX scores, and fragility fractures. Sole reliance on DEXA score cutoffs can lead to under-diagnosis and increased mortality risk for patients. Notably, any past fragility fracture in a postmenopausal woman is sufficient for an osteoporosis diagnosis. Dr. Beall shares that 82% of patients with fragility fractures do not have T-scores in the osteoporotic range. On the other hand, there are confounding factors that can give a falsely elevated T-score. As we shift to discussing medications for osteoporosis, Dr. Beall emphasizes the need to consider the order in which they are prescribed. He advocates for initially using osteo anabolics (specifically a PTH analog) for 2 years to build up bone mineral density, and then maintaining that density with antiresorptives afterwards. He notes that with the risk of bisphosphonate side effects like osteonecrosis of the jaw and atypical femur fracture, it is unwise to prescribe these antiresorptives as an initial treatment. Finally, we begin the conversation about vertebroplasty and recent trials proving its efficacy in reducing pain and improving function for patients. Tune in to our next 2 installments to learn about Dr. Beall's clinical pearls for vertebral augmentation! --- RESOURCES Dr. Douglas Beall Twitter: @DougBeall BackTable VI Episode 94, Innovation in Spine Interventions with Dr. Douglas Beall: https://www.backtable.com/shows/vi/podcasts/94/innovation-in-spine-interventions Comparison of thoracolumbosacral orthosis and no orthosis for the treatment of thoracolumbar burst fractures: interim analysis of a multicenter randomized clinical equivalence trial (2009): https://pubmed.ncbi.nlm.nih.gov/19769510/ Comparative study of the treatment outcomes of osteoporotic compression fractures without neurologic injury using a rigid brace, a soft brace, and no brace: a prospective randomized controlled non-inferiority trial (2014): https://pubmed.ncbi.nlm.nih.gov/25471910/ The efficacy of conservative treatment of osteoporotic compression fractures on acute pain relief: a systematic review with meta-analysis (2015): https://pubmed.ncbi.nlm.nih.gov/25725810/ Clinical effect of balloon kyphoplasty in elderly patients with multiple osteoporotic vertebral fracture (2019): https://pubmed.ncbi.nlm.nih.gov/30837413/

In this episode, host Dr. Jacob Fleming interviews Dr. Douglas Beall about current osteoporosis diagnosis criteria, his treatment algorithm, and recent data showing efficacy of osteoanabolic agents and vertebroplasty. --- CHECK OUT OUR SPONSOR DI4MDs Protect your most valuable asset, the skill and ability to practice your medical specialty. Be prepared by establishing a specialty specific disability insurance policy from the experts at DI4MDs. Contact them today at www.Di4MDS.com or call 888-934-4637. --- EARN CME Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs: https://earnc.me/oQMiwe --- SHOW NOTES In this episode, host Dr. Jacob Fleming interviews Dr. Douglas Beall about current osteoporosis diagnosis criteria, his treatment algorithm, and recent data showing efficacy of osteoanabolic agents and vertebroplasty. This is the second installment of our 4-part BackTable VI series on osteoporosis treatment. As we continue our conversation from Ep. 208, Dr. Beall outlines his typical follow up protocol for his patients. This includes DEXA scans in the first and second years, prescriptions for antiresorptive and/or osteoanabolic agents, and possible Romosozumab injections. Dr. Beall emphasizes that thoroughness is key to treating the disease process, and each encounter is a reimbursable event that can benefit both the patient and the practice. Next, we shift to talking about the American Association of Clinical Endocrinologists (AACE) diagnostic criteria for osteoporosis. Dr. Beall highlights the fact that there are 4 categories that encompass information about DEXA (T-scores), FRAX scores, and fragility fractures. Sole reliance on DEXA score cutoffs can lead to under-diagnosis and increased mortality risk for patients. Notably, any past fragility fracture in a postmenopausal woman is sufficient for an osteoporosis diagnosis. Dr. Beall shares that 82% of patients with fragility fractures do not have T-scores in the osteoporotic range. On the other hand, there are confounding factors that can give a falsely elevated T-score. As we shift to discussing medications for osteoporosis, Dr. Beall emphasizes the need to consider the order in which they are prescribed. He advocates for initially using osteo anabolics (specifically a PTH analog) for 2 years to build up bone mineral density, and then maintaining that density with antiresorptives afterwards. He notes that with the risk of bisphosphonate side effects like osteonecrosis of the jaw and atypical femur fracture, it is unwise to prescribe these antiresorptives as an initial treatment. Finally, we begin the conversation about vertebroplasty and recent trials proving its efficacy in reducing pain and improving function for patients. Tune in to our next 2 installments to learn about Dr. Beall's clinical pearls for vertebral augmentation! --- RESOURCES Dr. Douglas Beall Twitter: @DougBeall BackTable VI Episode 94, Innovation in Spine Interventions with Dr. Douglas Beall: https://www.backtable.com/shows/vi/podcasts/94/innovation-in-spine-interventions Comparison of thoracolumbosacral orthosis and no orthosis for the treatment of thoracolumbar burst fractures: interim analysis of a multicenter randomized clinical equivalence trial (2009): https://pubmed.ncbi.nlm.nih.gov/19769510/ Comparative study of the treatment outcomes of osteoporotic compression fractures without neurologic injury using a rigid brace, a soft brace, and no brace: a prospective randomized controlled non-inferiority trial (2014): https://pubmed.ncbi.nlm.nih.gov/25471910/ The efficacy of conservative treatment of osteoporotic compression fractures on acute pain relief: a systematic review with meta-analysis (2015): https://pubmed.ncbi.nlm.nih.gov/25725810/ Clinical effect of balloon kyphoplasty in elderly patients with multiple osteoporotic vertebral fracture (2019): https://pubmed.ncbi.nlm.nih.gov/30837413/

Episode 45: Osteoporosis Update. Dr Linares (endocrinologist) explains the basics of screening and treatment of osteoporosis, referring frequently to the updated guidelines of osteoporosis by AACE and ACE (2020). A new group of residents is introduced. Congratulations to our new group of residents:  Amelia Martinez Lopez, Amardeep Singh Chetha, Cecilia Selena Covenas, Funmilayo Helen Idemudia, Licet Imbert Matos, Su Myat Hlaing, Timiiye Dawn Yomi, and Young Na Sung. This group of residents will start in July 2021 and will graduate in July 2024. We hope you enjoy your time with us.Today is March 22, 2021.Implanted pacemakers and defibrillators are equipped with a switch that responds to magnetic forces to stop them when needed. Magnetic interference between these cardiac implantable electronic devices (CIEDs) and mobile devices have been investigated for years. It has been established that magnetic fields stronger than 10 gauss can deactivate these cardiac devices, causing pacemakers to give asynchronous pacing and ICDs to stop tachyarrhythmia detection.The Heart Rhythm Society journal, published in October 2009 (that was 11 years ago), an association between portable headphones and significant electromagnetic interference (EMI) in patients with implantable cardioverter-defibrillators (ICD) and pacemakers (PM). 100 patients with implanted devices were tested with different portable headphones. Headphones effectively deactivated implanted devices when held less than 2 cm from skin on the left side of chest. There was not interference when headphones were placed farther than 3 cm. In this study, normal functioning of the devices was restored in 29 out of 30 cases when the headphones were removed from the patient’s chest. The recommendation from that study was to recommend patients to keep their portable headphones at least 3 cm away from their implanted device.More recently, in January 2021, the same journal posted the effect of iPhone 12 on ICDs deactivation. iPhone 12 and MagSafe technology, which allows faster wireless charging, contain strong magnets. iPhone 12 successfully deactivated a Medtronic Inc. ICD when tested by a group of investigators in a patient[2]. The official Apple Support website posted on February 25, 2021, “To avoid any potential interactions with these devices, keep your iPhone and MagSafe accessories a safe distance away from your device (more than 6 inches / 15 cm apart or more than 12 inches / 30 cm apart if wirelessly charging)”[3]. Other devices such as fitness tracker wristbands, and even e-cigarettes have been involved in deactivation of ICDs.Bottom line: Make sure your patient discusses with you or their cardiologist before buying wearable or mobile technology that may interfere with their implanted cardiovascular devices.This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it’s sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. “The secret of getting ahead is getting started” —Mark Twain.Osteoporosis UpdateDuring this conversation, we discussed some parts of the guidelines from the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE)[2], updated in 2020. This is not a complete analysis of those guidelines. For a comprehensive explanation of the guidelines, visit the AACE or ACE websites. The recommendations from these organizations may be different than the ones given by the American Academy of Family Physicians (AAFP) or the United States Preventive Services Taskforce (USPSTF), which are organizations we are more familiar with as family physicians.The questions analyzed during this conversation includes:When would you consider a DEXA scan to screen a woman younger than 65 for osteoporosis? What to do when the report says Osteopenia (T score -1.0 to -2.5)? Let’s mention the recommended dose of Vitamin D and Calcium. What is the FRAX score?  What is an easy work up we can do to rule out a secondary cause of osteoporosis before sending patient to you? The new guidelines divide patients in two categories: “High risk/no risk of fractures” and “VERY High risk/prior fractures”, What’s the difference in management between those two categories? (alendronate in high risk vs abaloparatide in very high risk). How can you tell the patient has a good response after 1 year of treatment (Dexa scan, bone turnover markers)? What is a drug holiday? ___________________________Now we conclude our episode number 45 “Osteoporosis Update”. Dr Linares explained what the FRAX score is and mentioned the different options we have for treatment of osteoporosis. DEXA scan continues to be the gold standard for screening, diagnosis and monitoring of osteoporosis. We will announce the winner of the question of the month about polyarthralgia next week, and we wish our new group of residents a great start in July 2021. Remember, even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email RBresidency@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created with educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza, Maria Linares, and Claudia Carranza. Audio edition: Suraj Amrutia. See you next week! _____________________References:Lee S, Fu K, Kohno T, Ransford B, Maisel WH. Clinically significant magnetic interference of implanted cardiac devices by portable headphones. Heart Rhythm. 2009 Oct;6(10):1432-6. doi: 10.1016/j.hrthm.2009.07.003. Epub 2009 Jul 8. PMID: 19968922. https://www.heartrhythmjournal.com/article/S1547-5271(09)00740-1/fulltextGreenberg, Joshua C.; Mahmoud R. Altawil; Gurjit Singh; Letter to the Editor—Lifesaving Therapy Inhibition by Phones Containing Magnets, Heart Rhythm, January 04, 2021. DOI:https://doi.org/10.1016/j.hrthm.2020.12.032.  https://www.heartrhythmjournal.com/article/S1547-5271(20)31227-3/fulltext“About the magnets inside iPhone 12, iPhone 12 mini, iPhone 12 Pro, iPhone 12 Pro Max, and MagSafe accessories”, Apple Support, https://support.apple.com/en-us/HT211900, accessed on March 2, 2021. AACE Releases 2020 Clinical Practice Guidelines for Postmenopausal Osteoporosis, Physician Weekly, September 11, 2020, https://www.physiciansweekly.com/aace-releases-2020-update-clinical-practice-guidelines-for-postmenopausal-osteoporosis/

The president of the American Association of Clinical Endocrinologists (AACE) , Dr. Sandra Weber joins me to discuss the impact of Coronavirus on people with diabetes. Dr. Weber practices endocrinology in Greenville, South Carolina and is affiliated with Prisma Health System, where she serves as Chief of the Division of Endocrinology and Chair of Continuing Medical Education.  

The president of the American Association of Clinical Endocrinologists (AACE) , Dr. Sandra Weber joins me to discuss the impact of Coronavirus on people with diabetes. Dr. Weber practices endocrinology in Greenville, South Carolina and is affiliated with Prisma Health System, where she serves as Chief of the Division of Endocrinology and Chair of Continuing Medical Education.  

Dr. Christofides is dual board-certified in Endocrinology, Diabetes and Metabolism as well as Internal Medicine. She received both her undergraduate and medical degrees from The Ohio State University. She completed her internal medicine residency at Mount Carmel Medical Center and her fellowship training in Endocrinology, Diabetes and Metabolism at Louisiana State University Medical Center in New Orleans. She is a Fellow of the American Association of Clinical Endocrinologists (AACE), the highest honor in her specialty. She has served as President of the Ohio River Regional Chapter of AACE, President of the Ohio Chapter of the American Diabetes Association (ADA), Chair of the Medical Advisory Board of the Central Ohio Diabetes Association (CODA) and a member of its Board of Directors. She is affiliated with Mt. Carmel Hospitals and with Specialty Select Hospitals. Connect with Elena Christofides: https://endocrinology-associates.com/ https://www.realself.com/find/Ohio/Dublin/MediZen-Health https://shopwiththedoc.com/ Twitter: @DoctorEndocrine and @DrElena Connect with Nick Holderbaum: Personal Health Coaching: https://www.primalosophy.com/ Nick Holderbaum's Weekly Newsletter: Sunday Goods (T): @primalosophy (IG): @primalosophy iTunes: https://podcasts.apple.com/us/podcast/the-primalosophy-podcast/id1462578947 YouTube: https://www.youtube.com/channel/UCBn7jiHxx2jzXydzDqrJT2A The Unfucked Firefighter Challenge

Solidify your knowledge of osteoporosis and osteopenia in this discussion with Endocrinologists and osteoporosis guideline authors, Dr. Rachel Pessah-Pollack, and Dr. Dan Hurley from the American Association of Clinical Endocrinologists (AACE). Learn when to start therapy after an acute hip fracture, how to use bone turnover markers to assess fracture risk, more on how to dose calcium and vitamin D, and finally, we discuss the new American College of Physicians (ACP) guidelines and how they differ from the AACE guidelines on osteoporosis. For a more basic talk on osteoporosis check out episode #18 w/Dr. Pauline Camacho. Full show notes available at http://thecurbsiders.com/podcast Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Time Stamps 00:00 Intro 03:00 Picks of the week 07:31 Guest and topic intro 10:25 Rapid fire questions 14:45 Clinical Case and defining osteoporosis 17:00 FRAX score 20:35 Secondary evaluation for cause of bone loss 20:54 Bone turnover markers (telopeptides) 23:17 Alkaline phosphatase 26:30 Calcium and Vit D 29:35 Recap of teaching points so far 31:25 Antiresorptive versus anabolic therapy 32:40 Aromatase inhibitors increase fracture risk 34:28 When to start therapy after fracture 35:44 Mechanism of action recombinant PTH 41:38 Vitamin D assay and dosing 46:53 Calcium intake, and formulations 49:45 Take home points 50:54 Recap and discussion of AACE vs ACP guidelines by The Curbsiders 59:42 Outro Tags: bone, osteoporosis, anabolic, osteopenia, vitamin D, calcium, fracture, density, AACE, guidelines, assistant, care, education, doctor, family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, primary, physician, resident, student

Learn the latest in lipid lowering therapy in this extensive discussion with Dr. Paul S. Jellinger, MD, MACE, Professor of Medicine at the University of Miami and Chair of the writing committee for the American Association of Clinical Endocrinologists (AACE) 2017 Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease (CVD). Topics include ezetimibe, PCSK9, FOURIER trial, statin myopathy, CoQ10, fish oil, fibrates and more. For a more basic discussion of dyslipidemia check out episode #10. Full show notes are available at http://thecurbsiders.com/podcast Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Time Stamps 00:00 Intro 03:10 Rapid fire questions 08:15 Dyslipidemia defined 10:26 Classifying dyslipidemia 13:21 Diagnosing Familial Hypercholesterolemia 17:48 A difficult lipid case discussed 22:40 Lp (a), Apo B and LDL particle concentration 28:40 What labs to order 31:31 ACC/AHA versus other risk scores 38:21 IMPROVE-IT 41:35 Non-statin medications discussed 45:05 Hypertriglyceridemia fibrates and fish oil 48:25 How often to check the lipid panel 49:58 Statin Myopathy and CoQ10 54:17 FOURIER, PCSK9 and very low LDLs 59:43 Extreme risk category discussed 62:34 Is plaque regression possible? 64:12 Take home points 67:08 Outro Tags: assistant, care, cholesterol, doctor, education family, fish oil, foam, foamed, health, hospitalist, hospital, internal, internist, ldl, lipid, medicine, medical, myopathy, nurse, pcsk9, physician, practitioner, primary, statin, resident, student

An updated algorithm for type 2 diabetes management from the American Association of Clinical Endocrinologists (AACE) has been recently released. It includes new sections on lifestyle therapy, guiding principles, and incorporates all medications approved by the Food and Drug Administration through December 2015 for managing hyperglycemia, weight, blood pressure, and dyslipidemia. See the show notes and the specific algorithms here.

Dr. Davidson focuses on the key differences in the criteria of HbA1c goals of therapy (how and why) developed by the ADA, the American Association of Clinical Endocrinologists (AACE), and the American College of Endocrinology (ACE), and which guidelines PCPs should follow.

Guest: Daniel Einhorn, MD Host: Steven Edelman, MD The new American Association of Clinical Endocrinologists (AACE) guidelines represent a major shift in the way type 2 diabetes is treated. An emphasis on hypoglycemia, adherence to therapy and new medications are included in this new algorithm. Join host Dr. Steven Edelman and his guest, president-elect of AACE, Dr. Daniel Einhorn, as they discuss the principles underlying the new guidelines and how they differ from other guidelines.